4586
Medrx Co.,Ltd.
メドレックス
- Industry
- Pharmaceutical
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(thousand JPY)
Dec 2021
8,350
Dec 2022
59,482
Dec 2023
29,534
Dec 2024
257,915
Dec 2025
128,084
Operating profit(thousand JPY)
Dec 2021
-1,061,226
Dec 2022
-1,098,820
Dec 2023
-933,567
Dec 2024
-793,045
Dec 2025
-941,999
Operating profit margin(%)
Dec 2021
-12,709.29
Dec 2022
-1,847.32
Dec 2023
-3,160.99
Dec 2024
-307.48
Dec 2025
-735.45
Profit before tax(thousand JPY)
Dec 2021
-1,058,474
Dec 2022
-1,109,313
Dec 2023
-930,080
Dec 2024
-802,738
Dec 2025
-925,054
Profit(thousand JPY)
Dec 2021
-1,059,833
Dec 2022
-1,111,150
Dec 2023
-932,897
Dec 2024
-806,756
Dec 2025
-937,373
Total assets(thousand JPY)
Dec 2021
2,108,589
Dec 2022
1,398,266
Dec 2023
2,052,252
Dec 2024
2,275,600
Dec 2025
2,157,533
Cash and cash equivalents(thousand JPY)
Dec 2021
1,703,644
Dec 2022
994,025
Dec 2023
1,720,720
Dec 2024
1,977,638
Dec 2025
1,754,669
Cash flows from operating activities(thousand JPY)
Dec 2021
-923,688
Dec 2022
-1,073,292
Dec 2023
-913,800
Dec 2024
-803,403
Dec 2025
-888,109
Cash flows from investing activities(thousand JPY)
Dec 2021
-2,542
Dec 2022
-1,958
Dec 2023
-759
Dec 2024
-3,155
Dec 2025
-82,752
Cash flows from financing activities(thousand JPY)
Dec 2021
815,915
Dec 2022
356,315
Dec 2023
1,639,492
Dec 2024
1,066,994
Dec 2025
745,093
Return on equity(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Equity ratio(%)
Dec 2021
89.9
Dec 2022
82.2
Dec 2023
90.6
Dec 2024
92.9
Dec 2025
92.2
Earnings per share(JPY per share)
Dec 2021
-49.62
Dec 2022
-43.81
Dec 2023
-26.82
Dec 2024
-18.56
Dec 2025
-17.44
Net assets per share(JPY per share)
Dec 2021
77.09
Dec 2022
40.71
Dec 2023
48.44
Dec 2024
44.53
Dec 2025
33.51
Dividend per share(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Payout ratio(-)
Dec 2021
-
Dec 2022
-
Dec 2023
-
Dec 2024
-
Dec 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.